Loading cancer entity…
Loading cancer entity…
Clinical trials
242 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (46)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | recruiting | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06398457 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | recruiting | Early Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 1 |
| Sep 24, 2026 |
| clinicaltrials |
| NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | recruiting | Phase 1 / Phase 2 | 150 | Disc Medicine, IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT07469891 | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms | recruiting | Phase 1 | 100 | Prelude Therapeutics IncorporatedINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT04282187 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | recruiting | Phase 2 | 25 | University of WashingtonOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05875805 | A Telehealth Advance Care Planning Intervention(SICP RCT) | recruiting | N/A | 207 | University of RochesterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07228624 | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes | recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07302776 | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT | recruiting | Phase 1 | 50 | Stanford UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06361641 | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes(PHEMOP) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant | recruiting | Phase 1 | 46 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07250646 | A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis | recruiting | Phase 1 | 28 | Aspera Biomedicines, Inc.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07128381 | Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | recruiting | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03964506 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | recruiting | Early Phase 1 | 24 | Omar AljitawiOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07379125 | Therapeutic RSK1 Targeting in Myelofibrosis | recruiting | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07590986 | Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm | recruiting | — | 150 | Université Catholique de LouvainOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05835466 | Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | recruiting | Phase 2 | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06047886 | UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy | recruiting | Phase 1 | 50 | University of Alabama at BirminghamOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06351631 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | recruiting | Phase 3 | 400 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Apr 2, 2026 | clinicaltrials |
| NCT06063486 | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | recruiting | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05198960 | AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms(AVAJAK) | recruiting | Phase 3 | 1,308 | University Hospital, BrestOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation(ACCELERATE) | recruiting | Phase 2 | 358 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05123365 | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms | recruiting | Phase 1 / Phase 2 | 27 | University of California, IrvineOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | recruiting | Phase 2 | 216 | City of Hope Medical CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04942080 | Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)(CALRSUIVI) | recruiting | N/A | 260 | University Hospital, AngersOTHER_GOV | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07419178 | A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept(GR-MPN) | recruiting | N/A | 265 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) | recruiting | — | 5,000 | MPN Research FoundationOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03326310 | Selumetinib and Azacitidine in High Risk Chronic Blood Cancers | recruiting | Phase 1 | 18 | University of ChicagoOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06541249 | MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial(TREATMORE) | recruiting | Phase 2 | 54 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT06378437 | A Study of GLB-001 in Patients With Myeloid Malignancies | recruiting | Phase 1 | 108 | Hangzhou GluBio Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05423691 | Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs(TREG108) | recruiting | Phase 1 | 24 | Cellenkos, Inc.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT05488548 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 75 | Epigenetix, Inc.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
| NCT02760238 | Myeloproliferative Neoplasms (MPNs) Patient Registry | recruiting | — | 5,000 | University Health Network, TorontoOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06218628 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | recruiting | Phase 1 | 24 | Fox Chase Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT05882773 | Asian Myeloproliferative Neoplasm (MPN) Registry | recruiting | — | 1,000 | The University of Hong KongOTHER | 1 | May 31, 2023 | clinicaltrials |
Data updated 20 hours agoSource updated Sep 29, 2026source: clinicaltrials